VCAM1 and diabetic kidney disease: Furthermore, our in vitro study suggested that the FDA-approved drug disulfiram might alleviate interstitial inflammation and fibrosis by inhibiting tubular pyroptosis and VCAM1 expression in individuals with DKD.